Literature DB >> 24957850

An investigation of a PRESAGE® in vivo dosimeter for brachytherapy.

A K Vidovic1, T Juang, S Meltsner, J Adamovics, J Chino, B Steffey, O Craciunescu, M Oldham.   

Abstract

Determining accurate in vivo dosimetry in brachytherapy treatment with high dose gradients is challenging. Here we introduce, investigate, and characterize a novel in vivo dosimeter and readout technique with the potential to address this problem. A cylindrical (4 mm × 20 mm) tissue equivalent radiochromic dosimeter PRESAGE® in vivo (PRESAGE®-IV) is investigated. Two readout methods of the radiation induced change in optical density (OD) were investigated: (i) volume-averaged readout by spectrophotometer, and (ii) a line profile readout by 2D projection imaging utilizing a high-resolution (50 micron) telecentric optical system. Method (i) is considered the gold standard when applied to PRESAGE® in optical cuvettes. The feasibility of both methods was evaluated by comparison to standard measurements on PRESAGE® in optical cuvettes via spectrophotometer. An end-to-end feasibility study was performed by a side-by-side comparison with TLDs in an (192)Ir HDR delivery. 7 and 8 Gy was delivered to PRESAGE®-IV and TLDs attached to the surface of a vaginal cylinder. Known geometry enabled direct comparison of measured dose with a commissioned treatment planning system. A high-resolution readout study under a steep dose gradient region showed 98.9% (5%/1 mm) agreement between PRESAGE®-IV and Gafchromic® EBT2 Film. Spectrometer measurements exhibited a linear dose response between 0-15 Gy with sensitivity of 0.0133 ± 0.0007 ΔOD/(Gy ⋅ cm) at the 95% confidence interval. Method (ii) yielded a linear response with sensitivity of 0.0132 ± 0.0006 (ΔOD/Gy), within 2% of method (i). Method (i) has poor spatial resolution due to volume averaging. Method (ii) has higher resolution (∼1 mm) without loss of sensitivity or increased noise. Both readout methods are shown to be feasible. The end-to-end comparison revealed a 2.5% agreement between PRESAGE®-IV and treatment plan in regions of uniform high dose. PRESAGE®-IV shows promise for in vivo dose verification, although improved sensitivity would be desirable. Advantages include high-resolution, convenience and fast, low-cost readout.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24957850      PMCID: PMC4136760          DOI: 10.1088/0031-9155/59/14/3893

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  25 in total

1.  High dose-rate brachytherapy source localization: positional resolution using a diamond detector.

Authors:  T Nakano; N Suchowerska; M M Bilek; D R McKenzie; N Ng; T Kron
Journal:  Phys Med Biol       Date:  2003-07-21       Impact factor: 3.609

2.  A practical three-dimensional dosimetry system for radiation therapy.

Authors:  Pengyi Guo; John Adamovics; Mark Oldham
Journal:  Med Phys       Date:  2006-10       Impact factor: 4.071

3.  In vivo dosimeters for HDR brachytherapy: a comparison of a diamond detector, MOSFET, TLD, and scintillation detector.

Authors:  Jamil Lambert; Tatsuya Nakano; Sue Law; Justin Elsey; David R McKenzie; Natalka Suchowerska
Journal:  Med Phys       Date:  2007-05       Impact factor: 4.071

4.  Dosimetry of the microSelectron-HDR Ir-192 source using PRESAGE and optical CT.

Authors:  P Wai; J Adamovics; N Krstajic; A Ismail; A Nisbet; S Doran
Journal:  Appl Radiat Isot       Date:  2008-07-02       Impact factor: 1.513

5.  Current brachytherapy quality assurance guidance: does it meet the challenges of emerging image-guided technologies?

Authors:  Jeffrey F Williamson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008       Impact factor: 7.038

Review 6.  Radiation dosimetry using polymer gels: methods and applications.

Authors:  M McJury; M Oldham; V P Cosgrove; P S Murphy; S Doran; M O Leach; S Webb
Journal:  Br J Radiol       Date:  2000-09       Impact factor: 3.039

7.  In vivo dosimetry for gynaecological brachytherapy using a novel position sensitive radiation detector: feasibility study.

Authors:  B Reniers; G Landry; R Eichner; A Hallil; F Verhaegen
Journal:  Med Phys       Date:  2012-04       Impact factor: 4.071

8.  Toward acquiring comprehensive radiosurgery field commissioning data using the PRESAGE/optical-CT 3D dosimetry system.

Authors:  Corey Clift; Andrew Thomas; John Adamovics; Zheng Chang; Indra Das; Mark Oldham
Journal:  Phys Med Biol       Date:  2010-02-04       Impact factor: 3.609

9.  Feasibility of using PRESAGE® for relative 3D dosimetry of small proton fields.

Authors:  Li Zhao; Joseph Newton; Mark Oldham; Indra J Das; Chee-Wai Cheng; John Adamovics
Journal:  Phys Med Biol       Date:  2012-10-26       Impact factor: 3.609

10.  Physics-aspects of dose accuracy in high dose rate (HDR) brachytherapy: source dosimetry, treatment planning, equipment performance and in vivo verification techniques.

Authors:  Antony Palmer; David Bradley; Andrew Nisbet
Journal:  J Contemp Brachytherapy       Date:  2012-06-30
View more
  4 in total

1.  Dosimetric characteristics of a reusable 3D radiochromic dosimetry material.

Authors:  Jong Min Park; So-Yeon Park; Chang Heon Choi; Minsoo Chun; Ji Hye Han; Jin Dong Cho; Jung-In Kim
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 2.  Three-dimensional radiation dosimetry using polymer gel and solid radiochromic polymer: From basics to clinical applications.

Authors:  Yoichi Watanabe; Leighton Warmington; N Gopishankar
Journal:  World J Radiol       Date:  2017-03-28

Review 3.  A Review of PRESAGE Radiochromic Polymer and the Compositions for Application in Radiotherapy Dosimetry.

Authors:  Muhammad Zamir Mohyedin; Hafiz Mohd Zin; Mohd Zulfadli Adenan; Ahmad Taufek Abdul Rahman
Journal:  Polymers (Basel)       Date:  2022-07-16       Impact factor: 4.967

Review 4.  Radiation Dosimetry by Use of Radiosensitive Hydrogels and Polymers: Mechanisms, State-of-the-Art and Perspective from 3D to 4D.

Authors:  Yves De Deene
Journal:  Gels       Date:  2022-09-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.